Olimestra (Olmesartan Medoxomil)

Olmesartan Medoxomil, the active ingredient in Olimestra, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is used to treat hypertension in adult patients. GNH USA supplies Olimestra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olimestra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxomil is an ARB that lowers blood pressure by interfering with the renin‑angiotensin system.

- Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Heart failure: used as part of combination therapy to improve symptoms and outcomes. - Diabetic nephropathy: slows progression of kidney damage associated with diabetes. - Post‑myocardial infarction: assists in long‑term blood‑pressure control after an heart attack.

Adverse reactions to olmesartan may vary in frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea - Cough

Serious or Rare Side Effects: - Angio‑angry   - Hyperkalemia   - Acute kidney injury   - Liver enzyme elevation   - Severe hypotension  

Olimestra should be used with caution in several clinical situations.

- Renal impairment: dose may need adjustment and renal function should be monitored. - Hepatic impairment: use only if benefits outweigh risks. - Electrolyte disturbances: monitor potassium levels regularly. - Pregnancy: contraind  - Breastfeeding: contraind  - Store at room  :